Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Takeda plans to acquire GammaDelta for its solid tumor drug pipeline

The companies have been collaborators since 2017.

By Brian Buntz | October 27, 2021

Takeda/GammaDeltaTakeda Pharmaceutical Company Ltd. (TSE:4502/NYSE:TAK) is moving forward with its plan to acquire its collaborator GammaDelta Therapeutics Ltd. (London).

The acquisition is subject to customary closing conditions. Takeda projects that the deal will close in the first quarter of its fiscal year, which will end on June 30, 2022.

The acquisition would bolster Takeda’s immuno-oncology and immunotherapy portfolio. GammaDelta has experience working with gamma delta (γδ) T cells as potential therapies for solid tumors hematological malignancies.

GammaDelta had developed allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms. Those platforms encompass blood-derived and tissue-derived cells.

“We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors,” Christopher Arendt, head of oncology cell therapy and therapeutic area unit of Takeda said in a statement.

Arendt went on to say that γδ T-cell therapy platforms “represent a differentiated approach to target both solid tumors and hematological malignancies.”

The company’s allogenic blood-derived GDX012 variable δ1 and γδ T-cell platform is the most mature in its pipeline.

Earlier this year, GammaDelta announced that FDA had authorized an investigational new drug application as a potential treatment for hematological malignancies.

FDA also granted orphan drug designation to allogeneic Vδ1 γδ T cell therapy (GDX012) to treat acute myeloid leukemia.

Takeda and GammaDelta Therapeutics have been working together since 2017. GammaDelta was founded in 2016.


Filed Under: Oncology
Tagged With: gamma-delta, GammaDelta Therapeutics, immuno-oncology, immunotherapy, oncology, T cell therapy platforms, Takeda Pharmaceutical Co
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AstraZeneca/Daiichi-Sankyo
FDA approves Enhertu for HER2-low breast cancer
ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Olema Oncology
Olema Oncology’s OP-1250 could be a game-changing breast cancer drug
Merck in the Drug Discovery & Development Pharma 50
Merck halts Phase 3 Lynparza for futility

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50